- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01033565
Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders
August 25, 2023 updated by: University of Nebraska
Controlled-Release Melatonin (Melatonin CR)for the Treatment of Impaired Sleep Maintenance (ISM) in 4-8 Year Old Children With Autism Spectrum Disorders (ASD).
The purpose of this research is to see the effects (good and bad) of Melatonin CR on sleep in 4-8 year old children with autism spectrum disorders and sleep problems.
Study Overview
Detailed Description
The title of this acute, open-label pilot study is "Controlled Release Melatonin (Melatonin CR) for the treatment of impaired sleep maintenance (ISM) in 4-8 year old children with autism spectrum disorders (ASD)."
Maintenance of sleep is a significant challenge in the treatment of children with neurodevelopmental disabilities including ASDs.
Night awakening or early morning waking can have detrimental effects on these children's daytime behavior and the functioning of their household.
Sleep problems in the ASD population are generally managed first with behavioral interventions and, when these are not successful, pharmacologic therapy.
Most medications effect sleep onset and not sleep maintenance.
This study investigates the effectiveness of Melatonin CR for managing ISM in 4-8 year old children with ASD.
Twenty patients will be recruited from the Developmental/Behavioral Pediatrics Clinic at the Munroe Meyer Institute at the University of Nebraska Medical Center.
Inclusion criteria are male and female children ages 4-8 years with a diagnosis of an ASD, including Pervasive Developmental Disorder NOS (PDD, NOS), Asperger's Syndrome, or Autistic Disorder, parent/guardian consent for participation, stable psychotropic medication treatment for at least 4 weeks, and a documented history of ISM based on parent-report, somnolog and Child Sleep Habits Questionnaire (CSHQ), and a clinician rating of ≥4 (moderately ill) on the Clinical Global Impression-Severity (CGI-S) Scale.
Patients will be excluded if they have been treated with Melatonin or Melatonin CR in the past month, failed treatment with Melatonin CR, or if they have a previously un-evaluated medical condition which may be causing the ISM.
Following the completion of a somnolog and standardized questionnaires, the patients will be treated for 10-14 days with melatonin CR.
Somnologs will be completed during treatment, and standardized parent questionnaires, CGI-S, and adverse event collection will be repeated at the end of Melatonin CR therapy.
Response will be defined as a Clinical Global Impression-Improvement (CGI-I) score of 1 or 2 (much or very much improved).
These will be compared to baseline ratings.
Following the completion of the study protocol, all patients will continue to be followed in the Developmental Pediatrics clinic.
Data from this acute pilot trial can be used to evaluate the appropriateness of a larger study to determine optimal therapy for patients with ASD and ISM.
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198-5380
- University of Nebraska Medical Center-Munroe Meyer Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 6 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female children,
- ages 4-8 years,
- diagnosed with an ASD, including
- Pervasive Developmental Disorder NOS (PDD, NOS),
- Asperger's Syndrome, or
- Autistic Disorder, and followed in the Munroe Meyer Developmental Pediatrics Clinic. Documented impaired sleep maintenance (ISM) based on parent-report and 7 day somnolog (sleep diary).
- Clinician rating of 4 (moderately ill) or worse on CGI-S. Rating is based on the clinician's experience with evaluating and treating this patient population.
- Previous discussion during a clinic appointment about sleep difficulties, including review of sleep hygiene and basic behavioral interventions/strategies.
- Current problems of overnight awakenings recorded on the Children's Sleep Habits Questionnaire (CSHQ) despite behavioral intervention.
- Stable psychotropic medication treatment for the past 4 weeks.
Exclusion Criteria:
Treatment with Melatonin or Melatonin CR during the past month or previous failed treatment with Melatonin CR.
Presence of a previously unevaluated medical condition which may be the etiology of the nighttime awakenings. There is no contraindication for use of Melatonin CR in patients with obstructive sleep apnea.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Natrol
Subjects receive Natrol (sustained release melatonin) 5mg tablet 30 minutes prior to bedtime for 10 to 14 days
|
5mg of sustained released melatonin.
One tablet given 30 minutes prior to bedtime.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Global Impression-Improvement
Time Frame: 2 weeks
|
Assigns numerical score indicating level of improvement compared to baseline.
Scale is rated from 1-7: 1= very much improved; 2= much improved; 3= minimally improved; 4= no change; 5= minimally worse; 6= much worse; 7= very much worse.
|
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Howard Needelman, MD, University of Nebraska
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 4, 2010
Primary Completion (Actual)
October 1, 2010
Study Completion (Actual)
October 1, 2010
Study Registration Dates
First Submitted
December 14, 2009
First Submitted That Met QC Criteria
December 15, 2009
First Posted (Estimated)
December 16, 2009
Study Record Updates
Last Update Posted (Actual)
September 8, 2023
Last Update Submitted That Met QC Criteria
August 25, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Neurologic Manifestations
- Neurodevelopmental Disorders
- Child Development Disorders, Pervasive
- Sleep Wake Disorders
- Autism Spectrum Disorder
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Protective Agents
- Antioxidants
- Melatonin
Other Study ID Numbers
- 0401-09-FB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Disorder
-
Matrouh UniversitySuez Canal University; Beni-Suef University; University of Bisha, Saudia ArabiaCompletedSleep Disorder | Sleep Hygiene | Sleep Disorder; Insomnia Type | Sleep Disorder in Elderly | Sleep Disorder, Mental Health | Sleep Disorders, Physical HealthEgypt
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)CompletedSleep Disorder | Diarrhea | Anxiety Disorders | Insomnia | Sleep Initiation and Maintenance Disorders | Anxiety | Sleep Disturbance | Gastrointestinal Dysfunction | Heartburn | Caffeine | Caffeine Withdrawal | Caffeine; Sleep Disorder | Caffeine Dependence | Caffeine-Induced Anxiety Disorder | Caffeine-Induced Sleep... and other conditionsUnited States
-
Johannes Gutenberg University MainzRecruitingSleep Disorder | Restless Legs Syndrome | Insomnia | Sleep Apnea | Narcolepsy | Idiopathic Hypersomnia | Somnambulism | Sleep Disorder Parasomnia | REM Behavior DisorderGermany
-
Yale UniversityCompletedCircadian Rhythm Sleep Disorder, UnspecifiedUnited States
-
The University of Texas Health Science Center,...Active, not recruitingRapid Eye Movement Sleep Behavior DisorderUnited States
-
Merck Sharp & Dohme LLCCompletedDyssomnias | Sleep Disorders | Mental Disorder | Sleep Initiation and Maintenance Disorder; Elderly | Sleep Disorder, Intrinsic
-
Vanda PharmaceuticalsRecruitingSleep Disorder | Sleep Disturbance | Autism Spectrum Disorder | Neurological DisorderUnited States
-
Assistance Publique Hopitaux De MarseilleAix Marseille UniversitéRecruitingREM Sleep Behaviour DisorderFrance
-
Massachusetts General HospitalRecruitingRapid Eye Movement Sleep Behavior DisorderUnited States
-
Yale UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCritical Illness | Sleep Deprivation | Circadian Rhythm Sleep Disorder, UnspecifiedUnited States
Clinical Trials on Natrol
-
Duquesne UniversityCompleted
-
Vanderbilt UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Kufa UniversityCompletedKnee OsteoarthritisIraq